Taysha Gene Therapies, Inc. Long-Term Debt
Taysha Gene Therapies, Inc. (TSHA) had Long-Term Debt of $49.26 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation
us-gaap:LongTermDebtNoncurrent · last filed 2026-08-11
- 2026-06-30: Long-term Debt, Excluding Current Maturities $49.26M.
- 2026-03-31: Long-term Debt, Excluding Current Maturities $48.96M.
- 2025-12-31: Long-term Debt, Excluding Current Maturities $50.11M.
- 2025-09-30: Long-term Debt, Excluding Current Maturities $50.85M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2026-06-30 | $49.26M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $48.96M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $50.11M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $50.85M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $41.05M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $42.45M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $43.94M 10-K · filed 2026-03-19 |
| 2024-09-30 | $42.97M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $37.84M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $40.51M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $40.51M 10-K · filed 2025-02-26 |
| 2023-09-30 | $38.55M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $38.35M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $38.16M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $37.97M 10-K · filed 2024-03-19 |
| 2022-09-30 | $37.77M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $37.58M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $37.39M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $37.19M 10-K · filed 2023-03-28 |
| 2021-09-30 | $27.81M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |